Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study

Matthijs van der Meulen; Katerina Bakunina; M Nijland; MC Minnema; G Cull; WBC Stevens; JW Baars; KD Mason; A Beeker; M Beijert; MJ Taphoorn; Martin van den Bent; S Issa; Jeanette Doorduijn; Jacoline Bromberg; L Dirven

doi:10.1016/j.annonc.2020.04.014

Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study

Matthijs van der Meulen, Katerina Bakunina, M Nijland, MC Minnema, G Cull, WBC Stevens, JW Baars, KD Mason, A Beeker, M Beijert, MJ Taphoorn, Martin van den Bent, S Issa, Jeanette Doorduijn, Jacoline Bromberg, L Dirven

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

33 Downloads (Pure)

Original language	English
Pages (from-to)	1046-1055
Number of pages	10
Journal	Annals of Oncology
Volume	31
Issue number	8
DOIs	https://doi.org/10.1016/j.annonc.2020.04.014
Publication status	Published - 2020

Research programs

EMC MM-03-44-06
EMC OR-01

Access to Document

10.1016/j.annonc.2020.04.014

Repub_127715.pdfFinal published version, 520 KB

Cite this

van der Meulen, M., Bakunina, K., Nijland, M., Minnema, MC., Cull, G., Stevens, WBC., Baars, JW., Mason, KD., Beeker, A., Beijert, M., Taphoorn, MJ., van den Bent, M., Issa, S., Doorduijn, J., Bromberg, J., & Dirven, L. (2020). Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study. Annals of Oncology, 31(8), 1046-1055. https://doi.org/10.1016/j.annonc.2020.04.014

@article{f481ab996beb4bbfa8d7bef54ac0ba41,

title = "Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study",

author = "{van der Meulen}, Matthijs and Katerina Bakunina and M Nijland and MC Minnema and G Cull and WBC Stevens and JW Baars and KD Mason and A Beeker and M Beijert and MJ Taphoorn and {van den Bent}, Martin and S Issa and Jeanette Doorduijn and Jacoline Bromberg and L Dirven",

year = "2020",

doi = "10.1016/j.annonc.2020.04.014",

language = "English",

volume = "31",

pages = "1046--1055",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "8",

}

van der Meulen, M, Bakunina, K, Nijland, M, Minnema, MC, Cull, G, Stevens, WBC, Baars, JW, Mason, KD, Beeker, A, Beijert, M, Taphoorn, MJ, van den Bent, M, Issa, S, Doorduijn, J , Bromberg, J & Dirven, L 2020, 'Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study', Annals of Oncology, vol. 31, no. 8, pp. 1046-1055. https://doi.org/10.1016/j.annonc.2020.04.014

Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study. / van der Meulen, Matthijs; Bakunina, Katerina; Nijland, M et al.
In: Annals of Oncology, Vol. 31, No. 8, 2020, p. 1046-1055.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study

AU - van der Meulen, Matthijs

AU - Bakunina, Katerina

AU - Nijland, M

AU - Minnema, MC

AU - Cull, G

AU - Stevens, WBC

AU - Baars, JW

AU - Mason, KD

AU - Beeker, A

AU - Beijert, M

AU - Taphoorn, MJ

AU - van den Bent, Martin

AU - Issa, S

AU - Doorduijn, Jeanette

AU - Bromberg, Jacoline

AU - Dirven, L

PY - 2020

Y1 - 2020

U2 - 10.1016/j.annonc.2020.04.014

DO - 10.1016/j.annonc.2020.04.014

M3 - Article

C2 - 32371123

SN - 0923-7534

VL - 31

SP - 1046

EP - 1055

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

ER -